Your browser doesn't support javascript.
loading
Sphingolipid imbalance and inflammatory effects induced by uremic toxins in heart and kidney cells are reversed by dihydroceramide desaturase 1 inhibition.
Savira, Feby; Magaye, Ruth; Scullino, Carmen V; Flynn, Bernard L; Pitson, Stuart M; Anderson, Dovile; Creek, Darren J; Hua, Yue; Xiong, Xin; Huang, Li; Liew, Danny; Reid, Christopher; Kaye, David; Kompa, Andrew R; Wang, Bing Hui.
Afiliación
  • Savira F; Biomarker Discovery Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia; Monash Centre of Cardiovascular Research and Education in Therapeutics, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
  • Magaye R; Biomarker Discovery Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia; Monash Centre of Cardiovascular Research and Education in Therapeutics, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
  • Scullino CV; Monash Institute of Pharmaceutical Science, Monash University, Parkville, Australia.
  • Flynn BL; Monash Institute of Pharmaceutical Science, Monash University, Parkville, Australia.
  • Pitson SM; Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, Australia.
  • Anderson D; Monash Institute of Pharmaceutical Science, Monash University, Parkville, Australia.
  • Creek DJ; Monash Institute of Pharmaceutical Science, Monash University, Parkville, Australia.
  • Hua Y; Biomarker Discovery Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia; School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China.
  • Xiong X; Biomarker Discovery Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia; Monash Centre of Cardiovascular Research and Education in Therapeutics, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
  • Huang L; Biomarker Discovery Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia; Monash Centre of Cardiovascular Research and Education in Therapeutics, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
  • Liew D; Monash Centre of Cardiovascular Research and Education in Therapeutics, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
  • Reid C; School of Public Health, Curtin University, Perth, Australia.
  • Kaye D; Heart Failure Research Group, Baker Heart and Diabetes Institute, Melbourne, Australia.
  • Kompa AR; Department of Medicine, University of Melbourne, St Vincent's Hospital, Fitzroy, Victoria, Australia.
  • Wang BH; Biomarker Discovery Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia; Monash Centre of Cardiovascular Research and Education in Therapeutics, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia. Electronic address: bing.wang@baker.edu.au.
Toxicol Lett ; 350: 133-142, 2021 Oct 10.
Article en En | MEDLINE | ID: mdl-34303789
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Oxidorreductasas / Esfingolípidos / Toxinas Biológicas / Uremia / Enfermedades Cardiovasculares Límite: Animals / Humans Idioma: En Revista: Toxicol Lett Año: 2021 Tipo del documento: Article País de afiliación: Australia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Oxidorreductasas / Esfingolípidos / Toxinas Biológicas / Uremia / Enfermedades Cardiovasculares Límite: Animals / Humans Idioma: En Revista: Toxicol Lett Año: 2021 Tipo del documento: Article País de afiliación: Australia